Japan's Taisho Struggles Overseas In Q1 As Domestic Sales Recover
Executive Summary
Japan's Taisho posted OTC sales down 5% its first quarter, as turnover fell double-digits in its Europe and Americas region due to the ongoing impact of the COVID-19 pandemic.
You may also be interested in...
Japan's Taisho Establishes Global OTC Footprint With $1.6bn Acquisition of Bristol-Myers Squibb's UPSA
Taisho is striking out from its Asian base to create a global OTC player through the acquisition of Bristol-Myers Squibb's UPSA. The transaction will catapult it to the number-three spot in France and give it a foothold in a slew of important emerging markets.
Timely Acquisition Keeps Germany's Dermapharm Growing
With its Branded Pharmaceuticals division negatively impacted by the end of the COVID-19 pandemic, the timely acquisition of supplements firm Arkopharma ensured Dermapharm recorded double-digit sales growth in 2023.
Sweden Seeks To Tackle Opioid Overdose Deaths With Naloxone Rx-To-OTC Switch
Opioid antagonist naloxone will soon be available without prescription in Sweden following a successful Rx-to-OTC application from Norway's DNE Pharma.